logo

Karyopharm Therapeutics Inc. (KPTI)



Trade KPTI now with
  Date
  Headline
12/4/2018 7:05:24 AM Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/3/2018 7:15:32 AM Wedbush Reiterates Karyopharm Therapeutics Inc. (KPTI) At Outperform With $19 Price Target
12/1/2018 12:35:09 PM Karyopharm Reports Positive Top-Line Phase 2b SADAL Data For Selinexor At ASH 2018 Annual Meeting
11/9/2018 6:14:28 AM Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) FY19 Rev. Estimate To 15.7 M From 17.4 M
11/9/2018 6:14:15 AM Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) FY18 Rev. Estimate To 32.6 M From 34.7 M
11/9/2018 6:13:52 AM Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) FY19 Estimate To -3.63 From -3.01
11/9/2018 6:13:37 AM Wedbush Is Cutting Karyopharm Therapeutics Inc. (KPTI) Q4 19 Estimate To -0.92 From -0.73
11/9/2018 6:13:24 AM Wedbush Is Cutting Karyopharm Therapeutics Inc. (KPTI) Q3 19 Estimate To -0.86 From -0.73
11/9/2018 6:13:09 AM Wedbush Is Cutting Karyopharm Therapeutics Inc. (KPTI) Q2 19 Estimate To -0.95 From -0.78
11/9/2018 6:12:52 AM Wedbush Is Lowering Karyopharm Therapeutics Inc. (KPTI) Q1 19 Estimate To -0.90 From -0.77
11/9/2018 6:12:37 AM Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) FY18 Estimate To -3.00 From -3.09
11/9/2018 6:12:20 AM Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q4 18 Estimate To -0.83 From -0.87
11/9/2018 6:11:44 AM Wedbush Lifts Karyopharm Therapeutics Inc. (KPTI) To Outperform From Neutral With $19 Price Target
11/2/2018 7:18:43 AM Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10/29/2018 7:04:24 AM Karyopharm Therapeutics Reports Closing Of Additional $22.5 Mln Of 3.00% Convertible Senior Notes Due 2025
10/26/2018 7:08:35 AM Karyopharm Therapeutics CFO Mike Falvey To Leave To Pursue Other Interests
10/11/2018 7:03:55 AM Karyopharm Therapeutics Prices $150 Mln Of 3.00% Convertible Senior Notes Due 2025
10/9/2018 4:09:56 PM Karyopharm Therapeutics Announces Proposed Private Offering Of $150 Mln Of Convertible Senior Notes
10/1/2018 7:04:11 AM Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)